Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform

Young-Man Kwon¹, Hye Suk Hwang²,³, Young-Tae Lee¹,³, Ki-Hye Kim¹, Youri Lee¹, Min-Chul Kim¹,³, Yu-Na Lee¹,³, Fu-Shi Quan¹,³, Martin L. Moore⁶, Sang-Moo Kang¹,*

¹Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
²Department of Microbiology, Chonnam National University Medical School, Hwasun 58128, Korea
³Green Cross Cell Corp., Yongin 16924, Korea
⁴Komipharm Co., Ltd., Siheung 15094, Korea
⁵Animal and Plant Quarantine Agency, Gimcheon 39660, Korea
⁶Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Korea
⁷Meissa Vaccines, South San Francisco, CA 94080, USA

ABSTRACT

Formalin-inactivated respiratory syncytial virus (RSV) vaccination causes vaccine-enhanced disease (VED) after RSV infection. It is considered that vaccine platforms enabling endogenous synthesis of RSV immunogens would induce favorable immune responses than non-replicating subunit vaccines in avoiding VED. Here, we investigated the immunogenicity, protection, and disease in mice after vaccination with RSV fusion protein (F) encoding plasmid DNA (F-DNA) or virus-like particles presenting RSV F (F-VLP). F-DNA vaccination induced CD8 T cells and RSV neutralizing Abs, whereas F-VLP elicited higher levels of IgG2a isotype and neutralizing Abs, and germinal center B cells, contributing to protection by controlling lung viral loads after RSV challenge. However, mice that were immunized with F-DNA displayed weight loss and pulmonary histopathology, and induced F specific CD8 T cell responses and recruitment of monocytes and plasmacytoid dendritic cells into the lungs. These innate immune parameters, RSV disease, and pulmonary histopathology were lower in mice that were immunized with F-VLP after challenge. This study provides important insight into developing effective and safe RSV vaccines.

Keywords: RSV; F-VLP; F-DNA; Vaccine enhanced disease

INTRODUCTION

Human respiratory syncytial virus (RSV) causes bronchiolitis in infants and young children as well as severe respiratory illness in the elderly and immunocompromised adults (1,2). Human trials of formalin-inactivated RSV (FI-RSV) vaccines resulted in disastrous consequences of causing vaccine-enhanced disease (VED) during winter season (3). Mice immunized with...
FI-RSV in the alum formulation represented a model of recapitulating VED, suggesting that non-replicating vaccine-induced Th2 biased immune responses are associated with enhanced RSV disease (4-6).

DNA vaccines direct the production of mRNA and endogenously synthesize the vaccine proteins in vivo, subjecting to host post-translational modifications and making an authentic immunogen. This in vivo synthesis of RSV F proteins by DNA vaccines attributes the induction of Th1 profile immune responses of IgG2a isotype anti-F IgG and neutralizing Abs as well as cytotoxic CD8 T cells (7). RSV F-DNA boost vaccination was shown to switch preexisting Th2 anti-F responses toward Th1 type immune responses (7). Mice immunized with recombinant vaccinia virus expressing RSV attachment glycoprotein G (r-vaccinia G) were shown to develop eosinophilia similar to FI-RSV vaccination, whereas r-vaccinia F immunization of mice did not induce pulmonary eosinophils upon RSV challenge (8,9). Despite the difference in pulmonary eosinophil infiltration, r-vaccinia G or F immunization of mice displayed enhanced RSV disease such as weight loss after challenge (10-13). Strong induction of IFN-γ responses representing a Th1 profile was observed in mice with r-vaccinia G or F immunization (12-15). Thus, both endogenous and exogenous expression of RSV immunogens may have the potential to cause VED after RSV challenge. However, it is less well known whether RSV F-DNA vaccination would induce VED upon RSV challenge.

Virus-like particle vaccines presenting RSV F alone (F-VLP) were demonstrated to confer protection against RSV without displaying VED in mice (16,17). Since gene-based in vivo immunogen synthesizing approaches are considered as an RSV vaccine platform, it is important to better understand protection and disease after RSV F-DNA vaccination. In this study, we investigated the immunogenicity, protection, VED, and histopathology in a mouse model after vaccination with F-DNA, F-VLP, or FI-RSV followed by RSV challenge. This study suggests that F-DNA vaccine is less immunogenic and protective, causing overt weight loss and pulmonary histopathology compared to F-VLP upon RSV challenge in mice. Potential immune parameters possibly correlated with RSV disease were investigated and discussed.

**MATERIALS AND METHODS**

**Cells, virus, and RSV vaccines**

The RSV A2 strain was originally gifted from Dr. Barney Graham. Hep-2 cells were obtained from American Type Culture Collection and maintained in DMEM media. The expression plasmid encoding a full-length human codon-optimized RSV A2 F within the pcDNA3 plasmid was described in previous studies (18,19). F-VLP vaccine was produced in insect cells by co-expressing RSV F and influenza virus matrix 1 (M1) core protein and characterized as previously described (20). Briefly, Sf9 insect cells were co-transfected with recombinant baculoviruses expressing M1 and RSV F protein in serum-free SF900-II medium. The culture supernatants were collected by centrifugation (6,000 rpm, 20 min) to remove insect cells. The cleared supernatants containing F-VLPs were purified by ultracentrifugation. The purified F-VLPs were resuspended in PBS. F-DNA vaccine was purified using Qiagen Plasmid Mega Kit (Qiagen, Hilden, Germany). RSV was grown in HEp-2 cells, inactivated with formalin (1:4,000 vol/vol) for 3 days at 37°C, purified using ultracentrifugation to remove cell culture supernatants and cellular proteins, and finally confirmed by a modified immuno-plaque assay as previously described (20). Briefly, the infected Hep-2 cell plates were incubated at 37°C, 5% CO₂ for 16 h and then viral supernatants were removed. After
overlay with a mixture of 1% agarose and DMEM media, the infected Hep-2 cell plates were further incubated for 3 days, the infected Hep-2 cell plates were fixed with 10% formalin and then overlay agarose was removed. Viral plaques by RSV A2 were immune-stained with 131-2a monoclonal Ab and DAB substrate (Invitrogen, Carlsbad, CA, USA).

Vaccination, sample collection, and virus challenge
For F-VLP and F-DNA vaccine groups, BALB/c mice (6 to 8 wk old, n=5, duplicate) were intramuscularly primed and boosted with 20 µg F-VLP or 100 µg plasmid F-DNA at 0, 3 wk. Second boost vaccination was followed with a half dose of F-VLP (10 µg) or F-DNA (50 µg) respectively at wk 6. The FI-RSV control group was intramuscularly primed (wk 0) and boosted (wk 3) with FI-RSV (2 µg) in alum (50 µg) adjuvant. Each group of immunization and challenge experiments was duplicated. Naïve or vaccinated mice were challenged intranasally with RSV A2 strain (3.3×10⁵ PFU, plaque-forming units) 20 wk after 2nd boost. The individual lungs and bronchoalveolar lavage fluid (BALF) samples were collected day 5 post-challenge to determine inflammatory cellular responses (17,18). All animal experiments were approved by the Georgia State University Institutional Animal Care and Use Committees (IACUC A18001) and performed in accordance with relevant guidelines and regulations.

Assays for Ab responses, RSV neutralizing activity, and lung viral titers
RSV specific Abs (IgG, IgG1, and IgG2a) were determined by ELISA using RSV F protein antigen (BEI) and presented in concentrations based on standard IgG and isotypes as described (17). Neutralizing Ab titers in mouse sera were measured using the red fluorescent RSV A2-K-line19F (200 PFU per well) and lung viral titers by an immunoplaque assay as described (21,22).

Pulmonary histology of RSV-infected mice
Individual lungs were immersed in 10% neutral buffered formalin for 24 h, embedded in paraffin, sectioned, and stained with H&E, periodic acid-Schiff stain (PAS) or hematoxylin and congo red (H&CR) as described (22-24). For numerical assessment of histopathology and pneumonia in lung tissues, the bronchioles, vessels and interstitial space were initially scored on a scale of 0–3 by blinded observers with the severity scoring system as previously described (23,25). A score 1 was assigned when the epithelial lines, vessels, and interstitial surrounding spaces have few infiltrating cells, a score 2 when the epithelial lines and surrounding spaces contain focal aggregates of infiltrating cells or the structure is cuff by one definite layer of infiltrating cells, and a score 3 when structure is obviously cuff by two or more definite layers of infiltrating cells with focal aggregates.

Cell preparations and flow cytometry
BALFs were harvested from the lung airways by infusion with PBS via trachea using a 25-gauge catheter (26). Lung tissues were homogenized, passed through a cell strainer, and spun on 44/67% Percoll gradients to collect lung cells. Cellular phenotypes were determined by flow cytometric analysis using cell surface marker Abs specific for CD3, CD4, CD8, CD11b, CD11c, CD45, F4/80, Siglec F, DX5, and Ly6c (eBioscience, San Diego, CA, USA or BD Pharmingen, San Jose, CA, USA) as previously described (17,27,28). Cells from BALF and lungs were stimulated with the synthetic F₈₅₋₉₃ (KYKNAVTEL) peptide (29) for CD8 T cell activation. Intracellular cytokine-producing cells stained with monoclonal IFN-γ and TNF-α and cell phenotypic marker Abs were acquired by the Becton-Dickinson LSR-II/Fortessa flow cytometer and data analyzed by Flowjo software (Tree Star Inc., Ashland, OR, USA). In the determination of cellular phenotypes, the fraction (%) of each cell phenotypes obtained by
flow cytometry was multiplied by the total cell numbers counted in the cell preparations from the lung tissues and BALF.

**Statistical analysis**
Results are expressed as mean±SEM; statistical significance was calculated by one-way ANOVA, followed by Tukey’s Multiple Comparison test using GraphPad Prism software (GraphPad Inc., La Jolla, CA, USA). A p-value less than 0.05 was considered significant.

**RESULTS**

**F-VLP or F-DNA immunization induces IgG2a isotype dominant Ab responses**

To compare the immunogenicity of exogenous F-VLP and endogenous F-DNA vaccine platforms, RSV F protein antigen-specific Abs were determined in immune sera from immunized mice (Fig. 1). Prime dose of F-DNA vaccine induced low levels of RSV F specific IgG Abs, requiring multiple immunizations. Whereas, the F-VLP group of mice induced substantial levels of IgG and IgG2a isotype Abs specific for RSV F protein after prime immunization. Significant levels of RSV F protein specific IgG and IgG2a Abs were induced after second boost with F-DNA vaccine although they were lower than those induced by F-VLP boost (Fig. 1A-C). Both F-VLP and F-DNA vaccines preferentially raised IgG2a isotype dominant Ab responses (Fig. 1B) as evidenced by high IgG2a/IgG1 ratios of Ab responses (Fig. 1D). In contrast, FI-
RSV vaccination induced highest levels of IgG1 isotype Abs (Fig. 1C), suggesting Th2 immune responses. RSV neutralizing activity as measured by reduction percentages of fluorescent RSV virus infection and plaque assays was observed at higher levels in both immune sera from the F-VLP and F-DNA groups compared to naïve sera (Fig. 1E). Immune sera of alum adjuvanted FI-RSV vaccinated mice exhibited highest levels of RSV neutralizing activity (Fig. 1E).

F-DNA immunization causes RSV disease of weight loss after challenge
To assess the protective efficacy of F-VLP and F-DNA vaccines, immunized mice were challenged with RSV A2 at 20 wk after second boost. F-VLP immunized mice did not show body weight loss, but approximately 10% body weight loss was observed in the naïve mice infected with RSV (Naïve inf, Fig. 2A). In contrast, F-DNA immunized mice displayed significant weight loss up to 15% (Fig. 2A). The highest RSV titers in lungs were detected in unvaccinated naïve mice on day 5 post infection (Fig. 2B). Approximately 10-fold lower lung RSV titers were observed in F-DNA immune mice compared to naïve infection mice, significantly clearing lung viral loads. The F-VLP group lowered lung viral titers by over 200 folds near to the detection limit (Fig. 2B). The alum adjuvanted FI-RSV group effectively cleared lung viral loads below the detection limit (Fig. 2B).

F-DNA vaccination induces infiltrating histopathology upon RSV challenge
The lung tissue sections were examined by staining with H&E, PAS, or H&CR at 5 days after RSV challenge (Figs. 3 and 4). As expected, mice that were immunized with FI-RSV showed the highest degree of pulmonary histopathology. After RSV challenge, F-DNA vaccination was found to induce significant infiltrates in the interstitial spaces of the lungs, which were similar to or slightly lower than FI-RSV (Fig. 3A and B). Moderate levels of infiltrates were observed in the blood vessels and airways from F-DNA immune mice (Fig. 3D). Meanwhile unvaccinated naïve mice exhibited moderately higher levels of infiltrating histopathology in the interstitial spaces after RSV infection (Fig. 3A and B). F-VLP immune mice did not show overt histopathology infiltrates upon RSV infection.

Mucus production and eosinophilia are also considered RSV disease parameters. FI-RSV immunization showed the highest levels of PAS positive mucus production and H&CR

---

**Figure 2.** F-DNA immune mice display weight loss despite control of lung viral loads after challenge. Unvaccinated naïve or vaccinated BALB/C mice were intranasally challenged with RSV A2 (3.3×10^5 PFU) at 20 wk after 2nd boost. (A) Changes in body weight. Differences are marked between F-VLP and F-DNA. (B) RSV titers in lungs. Lungs from individual mouse (n=10) were collected on day 5 post challenge and titers determined by an immunoplaque assay. The same vaccine groups as in the Fig. 1 were challenged with RSV. Statistical significances are indicated between naïve inf and immune mice and between F-VLP and F-DNA. LOD, limit of detection; FI-RSV, FI-RSV boost immune mice; F-VLP and F-DNA, F-VLP or F-DNA 2nd boost immunized mice on day 5 post RSV challenge.

* p<0.05; ** p<0.01; *** p<0.001.
positive eosinophils upon RSV challenge (Fig. 4). F-DNA immunization caused low levels of eosinophils (Fig. 4B and D). The naïve and F-VLP groups did not display PAS positive spots and eosinophils in the lung sections (Fig. 4A and C).

**Inflammatory innate immune cells are recruited into the lungs in F-DNA immune mice upon RSV challenge**

Cellular phenotypes in lung (Fig. 5) and BALF (Fig. 6) were analyzed by flow cytometry using cell type-specific marker Abs at 5 days after RSV challenge. Alum-adjuvanted FI-RSV immune mice showed the highest levels of eosinophils (CD11b+CD11c−SiglecF+) in lung and BALF samples as well as plasmacytoid dendritic cells (pDC, B220+CD11c−F4/80−) in BALF. F-DNA immunized mice displayed higher levels of NK cells (CD3−DX5+), monocytes (CD11b+F4/80−Ly6C+high), eosinophils, and pDC in the lungs compared to F-VLP or naïve infection mice. Particularly, eosinophil and monocyte populations were increased by approximately 3-fold in F-DNA mice than those in F-VLP mice. We also observed increased levels in monocytes and pDCs in airway BALF samples from F-DNA immunized mice, compared to those in F VLP (Fig. 6).

**F-DNA is effective in inducing Th1 CD8 T cells whereas F-VLP in activating B cells upon RSV challenge**

We determined the levels of CD8 T cells producing IFN-γ and/or TNF-α cytokines in the lungs at 5 days after RSV challenge by a flow cytometry assay of intracellular cytokine staining. Lung cells from F-DNA immune mice showed significantly higher levels of RSV F85-93-specific IFN-γ or TNF-α positive CD8 T cells than F-VLP, FI-RSV immune or naïve infection mice (Fig. 5E and F).

Germinal center (GC) phenotypic B cells (IgD+B220−GL7+) in the mediastinal draining lymph node (MLN) were also analyzed by flow cytometry day 5 post challenge. F-VLP immunized
mice showed significantly higher levels of GC phenotypic B cells in line with increased levels of serum IgG Abs compared to F-DNA immunization. The F VLP group showed certain levels of IgA Abs in BALF but not the F-DNA group, but overall the IgA Ab levels were very low and no significant levels of IgM Ab levels were detected (data not shown).

**DISCUSSION**

Since the failure of alum-adjuvanted FI-RSV vaccine, non-replicating RSV subunit vaccine platforms would have potential safety concerns of causing VED in young naïve children. Here, we compared the immunogenicity, protection, and immunopathology of a full-length F-DNA vaccine for in vivo endogenous expression or F-VLP as an exogenous RSV F protein. Both RSV F-VLP and DNA vaccines were capable of inducing IgG2a isotype and RSV neutralizing Abs
and controlling lung viral loads upon RSV challenge better than unvaccinated naïve mice with RSV infection. F-VLP was more effective in controlling RSV loads than F-DNA. Unexpectedly, the mice with F-DNA vaccination showed substantial weight loss and pulmonary histopathology compared to F-VLP immune or naïve mice after RSV infection. The results in this study suggest that RSV immunity in mice induced by endogenous expression of RSV F does not necessarily avoid VED after RSV infection.

The nature of endogenous synthesis of the vaccine immunogen by DNA vaccines engenders the induction of relatively weak humoral and strong cellular immune responses. RSV F specific Abs were not detected after prime with F-DNA probably due to low transgene transduction and thus multiple F-DNA immunizations required to induce substantial levels of antigen specific IgG Abs. Despite relatively low levels of IgG Abs, significant reductions of lung RSV titers were reported with soluble secreted F protein-encoding DNA vaccination being 10-fold more effective than transmembrane F protein-encoding plasmid (7). Low efficacy of lung RSV clearance in the F-DNA group might be due to the expression of membrane-anchored form. However, pulmonary inflammation was observed in animal models with F-DNA (7,30), FI-RSV (7), and soluble F protein (31) vaccines despite significant clearance of lung RSV loads or below the detection limit.

Different platforms of RSV vaccines influence the cellular phenotypes infiltrating into the lungs upon RSV challenge. FI-RSV or r-vaccinia G-immunized mice were shown to exhibit severe eosinophilia upon RSV challenge (29,32). Substantial RSV histopathology was previously reported in mice with RSV F DNA vaccination despite the induction of neutralizing...
Abs, Th1 CD8 T cell responses, and reduction of RSV lung viral loads (7, 30), consistent with this current study. Particularly in a recent study by Ma et al. (30), the groups of mice were immunized 4 times with 30 µg of F DNA vaccines containing 5 or 20 copies of built-in CpG immune stimulating motifs. Ma et al. (30) demonstrated that the pV AX1 -F (5CpG motifs) group displayed a similar pattern of weight loss (>10%) as the PBS control after RSV challenge, whereas the pV AX1 -F (20CpG motifs) group showed a moderate level of weight loss (<9%). In this study, we found that the F-DNA (no CpG motif) group and FI-RSV control group exhibited a substantial weight loss (>10%), which is similar to the PBS and pV AX1 -F (5CpG motifs) group in the Ma et al.’s study (30). It is speculated that the overall outcomes in body weight changes after RSV challenge are similar but subtle differences might be due to the nature of F DNA vectors, doses, and immunization regimen between the two studies.

RSV F or G DNA vaccination was previously reported to infiltrate pulmonary eosinophils, NK cells, and neutrophils but histopathology was not investigated (33). F-DNA vaccine exhibited slightly higher levels of eosinophils than F-VLP vaccine after RSV challenge. However, the levels of eosinophils in the F-DNA group were significantly lower than those in FI-RSV immune mice after RSV challenge. F-DNA immune mice showed a Th1 pattern of immune responses (high IFN-γ, low IL-4, Supplementary Fig. 1), consistent with a pattern reported by Ma et al. (30). High eosinophils in the FI-RSV group were consistent with Th2 cytokine levels. Monocytes from the bone marrow traffic to peripheral tissues via the bloodstream in response to a signal of inflammation and play an important role in clearing pathogens (34). Additionally, extensive monocytes can contribute to immunopathology and degenerative disease (34). The pDCs are known to be important for

Figure 6. F-DNA immunization induces inflammatory innate cells and CD8 T cells in BALF after challenge. Flow cytometry of immune cells was applied to numerate cellular phenotypes in BALF at 5 days after RSV challenge (n=5). (A) NK (CD3−DX5+) cells, (B) monocytes (CD11b/F4/80/Ly6Chigh), (C) eosinophils (CD11b/CD11c/SiglecF+), (D) pDC (B220/CD11c/F4/80−), (E, F) CD8 T cells of intracellular cytokine staining after stimulation of BALF cells with RSV F−85-93 peptide. (E) BALF IFN-γ + CD8 T cells, (F) BALF TNF-α + CD8 T cells. Lines indicate differences between groups.

*p<0.05; **p<0.01; ***p<0.001.
producing type 1 IFNs and enhancing CD8 T cell responses (35,36). Other studies reported that high levels of pDCs are involved in severe RSV disease and elevated mortality during influenza virus infection (37,38). Levels of pDCs infiltrating into the lungs were shown to be correlated with FI-RSV VED (39). NK cells enhance CD8 T cells expressing IFN-γ and NK cell depletion was shown to attenuate weight loss during RSV infection (40,41). Consistent with previous studies, this study suggests that recruiting NK cells, monocytes, pDCs, and eosinophils at high levels in F-DNA immune mice contribute to pulmonary histopathology during RSV infection.

There was no significant difference in the levels of IL-4 cytokines in lung cells in response to stimulation with CD4 T and CD8 T cell epitopes between the F-DNA and F-VLP groups (Supplementary Fig. 1). Unbalanced high levels of CD8 T cell responses could induce significant immunopathology. Vaccination of mice with r-vaccinia G and M2, or M2<sub>62-90</sub> peptide in adjuvants inducing strong CD8 T cell responses was shown to cause severe weight loss after RSV challenge (29,42,43). Excess induction of IFN-γ T cell responses was shown to cause immune-mediated pathology in response to RSV infection (13,43-45). Also, high levels of TNF-α CD8 T cells were indicated to be an indicator for severity of pulmonary disease such as weight loss (46,47). In line with previous findings, F-DNA immune mice induced high levels of RSV F specific IFN-γ and TNF-α CD8 T cells in the lungs, compared to F-VLP, FI-RSV immune or naïve mice upon RSV challenge, suggesting a potential correlation with RSV disease. Interestingly, our previous studies reported that inclusion of F-DNA in the RSV F+G VLP vaccination was effective in controlling lung viral titers and preventing pulmonary histopathology (18,22,24). An appropriate balance of inducing CD8 T cells together with RSV neutralizing Abs would be important for conferring desirable protection avoiding VED during RSV infection.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grants AI093772, AI105170, and AI134132 to SMK.

SUPPLEMENTARY MATERIAL

Supplementary Figure 1

IFN-γ and IL-4 cytokines in BALF and cytokine-secreting lung cells after RSV challenge. (A, B) IFN-γ and IL-4 secreting cell responses from the lungs collected on day 5 post RSV challenge. Lung cells were <em>in vitro</em> cultured under stimulation with RSV F peptides, F<sub>85-93</sub> (CD8 T cell epitope) or F<sub>51-66</sub> (CD4 T cell epitope). The levels of IFN-γ (A) and IL-4 (B) were measured in the supernatants harvested after 72 h. (C, D) IFN-γ and IL-4 levels were determined in BALF samples collected at 5 days after RSV challenge. Lines indicate differences between groups.

Click here to view

REFERENCES

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* 2010;375:1545-1555.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med* 2005;352:1749-1759. [PUBMED] [CROSSREF]
3. Kapikian AZ, Mitchell RH, Chanock RM, Svedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. *Am J Epidemiol* 1969;89:405-421. [PUBMED] [CROSSREF]
4. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. *J Virol* 1994;68:5321-5325. [PUBMED]
5. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. *Vaccine* 1992;10:475-484. [PUBMED] [CROSSREF]
6. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. *J Immunol* 1993;151:2032-2040. [PUBMED]
7. Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. Protection against respiratory syncytial virus infection by DNA immunization. *J Exp Med* 1998;188:681-688. [PUBMED] [CROSSREF]
8. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. *Int Immunol* 1992;4:493-500. [PUBMED] [CROSSREF]
9. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. *J Exp Med* 1997;186:421-432. [PUBMED] [CROSSREF]
10. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. *J Exp Med* 1994;179:81-89. [PUBMED] [CROSSREF]
11. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. *J Virol* 1998;72:2871-2880. [PUBMED] [CROSSREF]
12. Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4+ T cells. *Immunity* 2001;15:637-646. [PUBMED] [CROSSREF]
13. Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. *J Virol* 2008;82:2196-2207. [PUBMED] [CROSSREF]
14. Srikiatkhachorn A, Chang W, Braciale TJ. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. *J Virol* 1999;73:6590-6597. [PUBMED] [CROSSREF]
15. Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. *J Immunol* 2000;165:6487-6495. [PUBMED] [CROSSREF]
16. Lee Y, Lee YT, Ko EJ, Kim KH, Hwang HS, Park S, Kwon YM, Kang SM. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles. *Hum Vaccin Immunother* 2017;13:2594-2605. [PUBMED] [CROSSREF]
17. Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM. Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells. *J Virol* 2015;89:11692-11705. [PUBMED] [CROSSREF]

https://immunenetwork.org

https://doi.org/10.4110/in.2019.19.e18

11/13
18. Ko EJ, Kwon YM, Lee JS, Hwang HS, Yoo SE, Lee YN, Lee YT, Kim MC, Cho MK, Lee YR, et al. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. *Nanomedicine (Lond)* 2015;11:99-108.

19. Stokes KL, Currier MG, Sakamoto K, Lee S, Collins PL, Plemper RK, Moore ML. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. *J Virol* 2013;87:10070-10082.

20. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. *J Infect Dis* 2011;204:987-995.

21. Hwang HS, Kim KH, Lee Y, Ko EJ, Ko EL, Park S, Lee JS, Lee BC, Kwon YM, Moore ML, et al. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats. *Hum Vaccin Immunother* 2017;13:1031-1039.

22. Hwang HS, Lee YT, Kim KH, Park S, Kwon YM, Lee Y, Ko EJ, Jung YJ, Lee JS, Kim YJ, et al. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease. *Virology* 2016;494:215-224.

23. Meyerholz DK, Griffin MA, Castilow EM, Varga SM. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. *Toxicol Pathol* 2009;37:249-255.

24. Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim YJ, Cho MK, Lee YT, Jung YJ, et al. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. *Antiviral Res* 2014;110:115-123.

25. Klopfleisch R. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review. *BMC Vet Res* 2013;9:123.

26. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. *Virology* 2010;405:165-175.

27. Ko EJ, Lee YT, Kim KH, Lee Y, Jung YJ, Kim MC, Lee YN, Kang T, Kang SM. Roles of aluminum hydroxide and monophosphoryl lipid a adjuvants in overcoming cd4+ t cell deficiency to induce isotype-switched IgG antibody responses and protection by t-dependent influenza vaccine. *J Immunol* 2017;198:279-291.

28. Lee YT, Ko EJ, Kim KH, Hwang HS, Lee Y, Kwon YM, Kim M, Lee YN, Jung Y, Kang SM. Cellular immune correlates preventing disease against respiratory syncytial virus by virus-like particle vaccine. *J Biomed Nanotechnol* 2017;13:84-98.

29. Olson MR, Varga SM. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. *Expert Rev Vaccines* 2008;7:1239-1255.

30. Ma Y, Jiao YJ, Yu YZ, Jiang N, Huay, Zhang XJ, Fu YH, Peng XL, Zheng YP, Anderson LJ, et al. A built-in CpG adjuvant in RSV F protein DNA vaccine drives a Th1 polarized and enhanced protective immune response. *Viruses* 2018;10:E38.

31. Schneider-Ohrum K, Cayette C, Bennett AS, Rajani GM, McTamney P, Nacel K, Hostetler L, Cheng L, Ren K, O’Day T, et al. Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus F primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (alum) adjuvant. *J Virol* 2017;91:e02180-16.

32. Castilow EM, Legge KL, Varga SM. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. *J Immunol* 2008;181:6692-6696.

33. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. *J Virol* 1999;73:7099-7107.
34. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol* 2011;11:762-774.

35. Boogaard I, van Oosten M, van Rijt LS, Muskens F, Kimman TG, Lambrecht BN, Buisman AM. Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. *Immunology* 2007;122:65-72.

36. Smit JI, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. *PLoS One* 2008;3:e1720.

37. Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, Ramilo O. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. *J Infect Dis* 2005;191:1105-1115.

38. Langlois RA, Legge KL. Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. *J Immunol* 2010;184:4440-4446.

39. Kim KH, Lee YT, Hwang HS, Kwon YM, Jung YJ, Lee Y, Lee JS, Lee YN, Park S, Kang SM. Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells. *PLoS One* 2015;10:e0139916.

40. Li F, Zhu H, Sun R, Wei H, Tian Z. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. *J Virol* 2012;86:2251-2258.

41. Harker JA, Yamaguchi Y, Culley FJ, Tregoning JS, Openshaw PJ. Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. *J Virol* 2014;88:604-611.

42. Simmons CP, Hussell T, Sparer T, Walzl G, Openshaw P, Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. *J Immunol* 2001;166:1106-1113.

43. Schmidt ME, Knudson CJ, Hartwig SM, Pewe LL, Meyerholz DK, Langlois RA, Harty JT, Varga SM. Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. *PLoS Pathog* 2018;14:e1006810.

44. Ostler T, Davidson W, Ehl S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. *Eur J Immunol* 2002;32:2117-2123.

45. Hussell T, Baldwin CJ, O’Garra A, Openshaw PJ. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. *Eur J Immunol* 1997;27:3341-3349.

46. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. *Eur J Immunol* 2001;31:2566-2573.

47. Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. *J Immunol* 2010;185:2382-2392.

https://doi.org/10.4110/in.2019.19.e18